Artiva Biotherapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
ARTV$4.06-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| NINE MONTHS ENDED SEPTEMBER 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities: | ||
| Net loss | $(77,343) | $(63,093) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation and amortization | 2,112 | 1,931 |
| Stock-based compensation | 6,262 | 5,232 |
| Unrealized loss on cash equivalents | (3) | — |
| Accretion of discounts and amortization of premiums on investments, net | (806) | (1,589) |
| Changes in operating assets and liabilities: | ||
| Other receivables (including related party amounts of $61 and $(37), respectively) | 46 | 67 |
| Prepaid expenses and other current assets | (2,535) | (3,420) |
| Other long-term assets | (851) | (151) |
| Accounts payable (including related party amounts of $0 and $(276), respectively) | 1,538 | (610) |
| Accrued expenses (including related party amounts of $35 and $(702), respectively) | 1,611 | (362) |
| Operating lease right-of-use asset and lease liabilities, net | 217 | (30) |
| Net cash used in operating activities | (69,752) | (62,025) |
| Investing activities: | ||
| Purchases of property and equipment | (1,702) | (2,166) |
| Purchases of investments | (241,915) | (37,336) |
| Maturities of investments | 64,814 | 86,873 |
| Net cash (used in) provided by investing activities | (178,803) | 47,371 |
| Financing activities: | ||
| Proceeds from public offering of common stock and issuance of pre-funded warrants | 300,000 | — |
| Issuance costs paid in connection with public offering of common stock and issuance of pre-funded warrants | (17,276) | — |
| Proceeds from exercise of stock options | 337 | 138 |
| Proceeds from purchase of ESPP shares | 325 | 233 |
| Payments to taxing authorities related to net-settlement of vested restricted stock units | (210) | (143) |
| Payments on finance leases | (45) | (98) |
| Net cash provided by financing activities | 283,131 | 130 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 34,576 | (14,524) |
| Cash, cash equivalents and restricted cash at beginning of period | 27,162 | 40,493 |
| Cash, cash equivalents and restricted cash at end of period | $61,738 | $25,969 |
| Reconciliation of cash, cash equivalents and restricted cash to the balance sheet: | ||
| Cash and cash equivalents | $61,234 | $25,508 |
| Restricted cash | 504 | 461 |
| Total cash, cash equivalents and restricted cash | $61,738 | $25,969 |
| Supplemental disclosures of noncash activities: | ||
| Reduction in operating lease liabilities and right-of-use-assets from remeasurement | $— | $546 |
| Property and equipment purchases in accounts payable and accrued expenses | $204 | $426 |
| Right-of-use asset obtained in exchange for new operating lease liability | $— | $442 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.